Subtypes of irritable bowel syndrome in children and adolescents

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 9, 2014, Pages 1468-1473

  Self, Mariella M ^a,b   Czyzewski, Danita I ^a,b   Chumpitazi, Bruno P ^a,b   Weidler, Erica M ^a,b,c   Shulman, Robert J ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c CHILDREN S NUTRITION RESEARCH CENTER   (United States)

Author keywords

Children; IBS subtypes; Irritable bowel syndrome; Pediatric functional GI disorders

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; ETHNICITY; FECES; FEMALE; HUMAN; IRRITABLE BOWEL SYNDROME WITH DIARRHEA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MIXED TYPE IRRITABLE BOWEL SYNDROME; PROSPECTIVE STUDY; TERTIARY CARE CENTER; UNSUBTYPED IRRITABLE BOWEL SYNDROME; ABDOMINAL PAIN; DEMOGRAPHY; DISEASE SEVERITY; MEDICAID; CLASSIFICATION; ITALY; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; CHILD; CONSTIPATION; DIARRHEA; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PAIN; PROSPECTIVE STUDIES; ROME; SEVERITY OF ILLNESS INDEX;

EID: 84906790800     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.01.031     Document Type: Article

References (32)

1. Longstreth G.F., Thompson W.G., Chey W.E., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
2. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
3. Camilleri M., Chey W.Y., Mayer E.A., et al. Arandomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
4. Chey W.D. Review article: tegaserod - the global experience. Aliment Pharmacol Ther 2004, 20(Suppl 7):15-19.
5. Muller-Lissner S.A., Fumagalli I., Bardhan K.D., et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655-1666.
6. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009, 29:329-341.
7. Johnston J.M., Kirtz C.B., MacDougall J.E., et al. Linaclotide improves abdominal pain and bowel habits in a phase Iib study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010, 139:1877-1886.
8. Engsbro A.L., Simren M., Bytzer P. The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterol Motil 2012, 24. 604-e266.
9. Engsbro A.L., Simren M., Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 2012, 35:350-359.
10. Palsson O., Baggish J., Turner M., et al. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012, 107:286-295.
11. Anbardan S.J., Daryani N.E., Fereshtehnejad S., et al. Gender role in irritable bowel syndrome: a comparison of irritable bowel syndrome module (Rome III) between male and female patients. JNeurogastroenterol Motil 2012, 18:70-77.
12. Dorn S.C., Morris C.B., Hu Y., et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. JClin Gastroenterol 2009, 43:214-220.
13. Ersryd A., Posserud I., Abrahamsson H., et al. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther 2007, 26:953-961.
14. Devanarayana N.M., Adhikari C., Pannala W., et al. Prevalence of functional gastrointestinal diseases in a cohort of Sri Lankan adolescents: comparison between Rome II and Rome III criteria. JTrop Pediatr 2011, 57:34-39.
15. Rajindrajith S., Devanarayana N.M. Subtypes and symptomatology of irritable bowel syndrome in children and adolescents: a school-based survey using Rome III criteria. JNeurogastroenterol Motil 2012, 18:298-304.
16. Coletta M., Di Palma L., Tombra C., et al. Discrepancy between recalled and recorded bowel habits in irritable bowel syndrome. Aliment Pharmacol Ther 2010, 32:282-288.
17. Chogle A., Sztainberg M., Bass L., et al. Accuracy of pain recall in children. JPediatr Gastroenterol Nutr 2012, 553:288-291.
18. Saulner D.M., Riehle K., Mistretta T., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011, 141:1782-1791.
19. Czyzewski D.I., Lane M.M., Weidler E.M., et al. The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children. Aliment Pharmacol Ther 2011, 33:403-411.
20. Rasquin A., Di Lorenzo C., Forbes D., et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006, 130:1527-1537.
21. von Baeyer C.L., Spagrud L.J., McCormick J.C., et al. Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity. Pain 2009, 143:223-227.
22. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32:920-924.
23. Wong R.K., Palsson O.S., Turner M.J., et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010, 105:2228-2234.
24. Garrigues V., Mearin F., Badia X., et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007, 25:323-332.
25. Mearin F., Varo E., Roset M., et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroeterol 2004, 99:113-121.
26. Williams R.E., Black C.L., Kim H.Y., et al. Stability of irritable bowel syndrome using a Rome II-based classification. Aliment Pharmacol Ther 2006, 23:197-205.
27. Hellstrom P.M., Saito Y.A., Bytzer P., et al. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol 2011, 106:1299-1307.
28. Camilleri M., Lasch K., Zhou W. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012, 303:G775-G785.
29. Matricon J., Meleine M., Gelot A., et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012, 36:1009-1031.
30. Drossman D.A., Morris C.B., Hu Y., et al. Aprospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005, 128:580-589.
31. Guilera M., Balboa A., Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005, 100:1-11.
32. Cohen J. Statistical power analysis for the behavioral sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ. 2nd ed.